APCU25OS12 Novel approach of in vitro study for coronary artery disease (CAD) treatment: the role of human umbilical cord blood-mesenchymal stem cells secretome and dapagliflozin in enhancing angiogenesis potential of endothelial progenitor cells in patients with stable cad under hypoxic preconditioning

Introduction Coronary artery disease (CAD) remains a significant global health burden, particularly for patients who are ineligible for revascularization. Therapeutic angiogenesis is a promising regenerative strategy aimed at restoring myocardial perfusion. The secretome derived from human umbilical cord blood mesenchymal stem cells (hUCB-MSCs) contains paracrine factors that promote new vessel formation, while dapagliflozin provides complementary pro-angiogenic effects. Hypoxic preconditioning enhances the responsiveness of endothelial progenitor cells (EPCs) and may further potentiate these interventions. This study evaluated the combined effects of the hUCB-MSC secretome and dapagliflozin on EPC angiogenesis under normoxia and hypoxia.Methods EPCs were isolated from peripheral blood of stable CAD patients and divided into normoxic and 48-hour hypoxic preconditioning groups. Each group was further stratified into control, treatment with 20% hUCB-MSC secretome, and treatment with 20% secretome plus 50 μM dapagliflozin. Angiogenesis was assessed by tube formation assay analyzed with ImageJ software and by ELISA measurement of endothelial nitric oxide synthase (eNOS) and von Willebrand factor (VWF). Data were analyzed using one-way ANOVA followed by post-hoc testing.Results Secretome treatment enhanced tube formation with a 42.3 ± 8.7% increase compared to the control (p